OSTEOPORE LIMITED — Board/Management Information 2022

Feb 14, 2022

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

Resignation of Non-Executive Director

15 February 2022: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale empowering natural tissue regeneration wishes to advise that it has accepted the resignation of Non-Executive Senior Independent Director Vlado Bosanac, effective 14 February 2022. The Company sincerely thanks Mr Bosanac for his contribution and wishes him the very best for the future.

Mr Bosanac said, “I have always been open and transparent in regard to my personal dispute with the Australian Tax Office (ATO). I feel it is best I step aside and continue to try and resolve this personal issue. I am passionate about the brilliance of the science behind OSX and its applicability to so many needed areas of medicine.”

Mark Leong, Osteopore’s Chairman commented: “It is with regret we accept Vlado’s resignation and we respect his decision to focus on his personal issue. I wish to thank Vlado for his insights during his time with Osteopore and we will explore how to continue to tap on Vlado’s considerable experience. We thank him for his passion and strong belief in the science and applications of our technology to improve lives.”

Osteopore has an active process of Board renewal and will continue to seek to expand the depth and breadth of its director skillsets and expertise.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman Osteopore Limited +65 9011 7009 Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [130 x 44] intentionally omitted <==

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com